- Report
- February 2026
- 501 Pages
Global
From €6102EUR$6,995USD£5,314GBP
- Report
- September 2025
- 250 Pages
Global
From €3917EUR$4,490USD£3,411GBP
- Report
- February 2026
- 274 Pages
Global
From €5103EUR$5,850USD£4,444GBP
- Report
- February 2026
- 529 Pages
Global
From €6102EUR$6,995USD£5,314GBP
- Report
- February 2026
- 354 Pages
Global
From €6102EUR$6,995USD£5,314GBP
- Report
- February 2026
- 677 Pages
Global
From €6102EUR$6,995USD£5,314GBP
- Report
- February 2026
- 414 Pages
Global
From €6102EUR$6,995USD£5,314GBP
- Report
- August 2025
- 124 Pages
Global
From €3488EUR$3,999USD£3,038GBP
- Report
- April 2025
- 235 Pages
Global
From €2181EUR$2,500USD£1,899GBP
- Report
- July 2025
- 175 Pages
Global
From €3917EUR$4,490USD£3,411GBP
- Report
- February 2026
- 367 Pages
Global
From €5103EUR$5,850USD£4,444GBP
- Report
- January 2026
- 185 Pages
Global
From €3436EUR$3,939USD£2,992GBP
- Report
- January 2026
- 181 Pages
Global
From €3436EUR$3,939USD£2,992GBP
- Report
- August 2025
- 191 Pages
Global
From €3436EUR$3,939USD£2,992GBP
- Report
- August 2025
- 180 Pages
Global
From €3436EUR$3,939USD£2,992GBP
- Report
- January 2026
- 197 Pages
Global
From €3436EUR$3,939USD£2,992GBP
- Report
- January 2026
- 181 Pages
Global
From €3925EUR$4,500USD£3,419GBP
- Report
- January 2026
- 181 Pages
Global
From €3925EUR$4,500USD£3,419GBP
- Report
- January 2026
- 185 Pages
Global
From €3925EUR$4,500USD£3,419GBP
- Report
- January 2026
- 180 Pages
Global
From €3925EUR$4,500USD£3,419GBP

The Syndromic Multiplex Diagnostic market is a subset of the Diagnostics industry that focuses on the development and commercialization of multiplex assays. These assays are used to detect multiple biomarkers from a single sample, allowing for the simultaneous diagnosis of multiple diseases or conditions. Multiplex assays are used in a variety of clinical settings, including infectious disease, oncology, and autoimmune disease.
The Syndromic Multiplex Diagnostic market is driven by the increasing demand for rapid and accurate diagnosis of multiple diseases. This demand is driven by the need for improved patient outcomes, cost savings, and the ability to diagnose multiple diseases in a single test.
Some companies in the Syndromic Multiplex Diagnostic market include Abbott, Bio-Rad, Cepheid, Luminex, and Qiagen. Show Less Read more